This amplicon encompasses many genes and it is conceivable that, as suggested by the variability of response to anti-ERBB2 therapy in patients with ERBB2 amplification, more than one gene in the amplicon could contribute to breast cancer susceptibility, development and progression (Willis et al, 2003). Here, ERBB2 is linked to breast cancer.